D. Boral Capital Reaffirms “Buy” Rating for FibroBiologics (NASDAQ:FBLG)

FibroBiologics (NASDAQ:FBLG)‘s stock had its “buy” rating reaffirmed by research analysts at D. Boral Capital in a note issued to investors on Thursday,Benzinga reports. They currently have a $16.00 price objective on the stock.

A number of other equities analysts have also weighed in on FBLG. Rodman & Renshaw initiated coverage on FibroBiologics in a research note on Thursday, December 12th. They set a “buy” rating and a $12.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of FibroBiologics in a report on Thursday. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, FibroBiologics presently has an average rating of “Buy” and a consensus price target of $13.00.

FibroBiologics Stock Down 23.7 %

FBLG traded down $0.41 on Thursday, reaching $1.32. The company had a trading volume of 862,288 shares, compared to its average volume of 365,524. FibroBiologics has a fifty-two week low of $1.08 and a fifty-two week high of $17.75. The company’s fifty day moving average is $1.98 and its 200 day moving average is $2.49.

Hedge Funds Weigh In On FibroBiologics

Hedge funds have recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company bought a new stake in shares of FibroBiologics during the 3rd quarter valued at $32,000. Jane Street Group LLC acquired a new position in FibroBiologics in the third quarter valued at about $37,000. Intech Investment Management LLC bought a new stake in FibroBiologics during the fourth quarter worth about $25,000. Virtu Financial LLC acquired a new stake in FibroBiologics during the fourth quarter worth about $30,000. Finally, Raymond James Financial Inc. bought a new position in FibroBiologics in the 4th quarter valued at about $37,000.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.